Summary
The cytotoxicity of the investigational anticancer drugs fluoro-ara-AMP, homoharringtonine, and elliptinium on normal human granulocyte-macrophage colony-forming units in culture (GM-CFU) was investigated using a bilayer soft agar system. For each drug, the dose-dependent survival curve on a semilogarithmic plot formed a straight line. The Do were: 0.51 μg/ml (fluoro-ara-AMP), 0.004 μg/ml (homoharringtonine) and 0.026 μg/ml (elliptinium). The in vitro toxicity of drugs on bone marrow progenitor cells did not correlate with the relative myelosuppressive potency observed in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Plunket W, Chubb S, Alexander L, Montgomery JA: Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-arabinofuranosyladenine. Cancer Res 40:2349–2355, 1980
Avramis VI, Plunkett W: Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine againstmurine leukemia P388. Cancer Res 42:2587–2591, 1982
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Sciences: The anti-tumor effect and pharmacologic actions of harringtonine. Chin Med J 3:131–136, 1977
Chinese People's Liberation Army, 187th Hospital: Harringtonine in acute leukemias: clinical analysis of 31 cases. Chin Med J 3:319–324, 1977
Neidhart JA, Young DC, Derocher D, Metz EN: Phase I trial of homoharringtonine. Cancer Treat Rep 67:801–804, 1983
Coonley CJ, Warrell RP, Young CW: Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep 67:693–696, 1982
Paoletti C, Le Pecq JB, Dat-Xuong N, Juret P, Gamier H, Amiel JL, Rouesse J: Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). In: Mathe G, Muggia FM (eds): Recent Results Cancer Res 74:107–123, 1980
Juret P, Tanguy A, Girard A, LeTalaer JY, Abbatucci JS, Dat-Xuong N, Le Pecq JB, Paoletti C: Preliminary trial of 9-hydroxy-20-methyl ellipticinium (NSC 264–137) in advanced human cancers. Eur J Cancer 14:205–206, 1978
Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287–300, 1966
Verma DS, Spitzer G, Beran M, Zander A, McCredie KB, Dicke K: Colony stimulating factor: augmentation in human placental conditioned medium. Exp Hematol 8:917–923, 1980
Drewinko B, Roper PR, Barlogie B: Patterns of cell survival following treatment with antitumor agents in vitro. Eur J Cancer 15:93–99, 1979
Park CH, Wiernik PH, Morrison FS, Amare M, Van Sloten KV Maloney TR: Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Cancer Res 43:2346–2349, 1983
Von Hoff DD: Phase I clinical trial of 2-Fluoro-ara-AMP-San Antonio. In: Investigational Drug Branch, National Cancer Institute (ed): Minutes of the Phase I Working Group Meeting. NCI, Bethesda, Maryland, 13–14 June,1983
Jiang TL, Liu RH, Salmon SE: Comparative in vitro antitumor activity of homoharringtonine and harringtonine against tumor cells. Invest N Drugs 1:21–25, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Umbach, G.E., Hug, V., Spitzer, G. et al. Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium. Invest New Drugs 2, 263–265 (1984). https://doi.org/10.1007/BF00175374
Issue Date:
DOI: https://doi.org/10.1007/BF00175374